Name: Phentolamine methanesulfonate salt | Phentolamine methanesulfonate; Phentolamine mesylate
Brand: Ambeed
SKU: A320047
Rating: 4.9 (131 reviews)

CAS No. :	65-28-1
Formula :	C₁₈H₂₃N₃O₄S
M.W :	377.46
SMILES Code :	CS(O)(=O)=O.CC1=CC=C(N(C2=CC(O)=CC=C2)CC3=NCCN3)C=C1
Synonyms :	Phentolamine methanesulfonate; Phentolamine mesylate; Phentolamine (mesylate)
MDL No. :	MFCD00134201
InChI Key :	OGIYDFVHFQEFKQ-UHFFFAOYSA-N
Pubchem ID :	91430

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302+H312+H332-H315-H319-H335
Precautionary Statements:	P261-P280-P301+P312+P330-P305+P351+P338

Rabbit aortic spiral strips	0.1 µM	2 hours	To investigate the inhibitory effect of phentolamine on ergonovine-induced contractions in normal and atherosclerotic rabbit aortic spiral strips. Results showed that 0.1 μM phentolamine inhibited 1 μM ergonovine-induced contractions by 71% in normal arteries, while the same concentration of phentolamine only inhibited 54% in atherosclerotic arteries.	Mediation by a serotonergic mechanism. J Clin Invest.
Human periodontal ligament fibroblasts (HPDLFs)	25 µM	24 hours or 48 hours	To investigate the effect of phentolamine on LPS-inhibited HPDLF proliferation, results showed that phentolamine significantly ameliorated LPS-inhibited cell proliferation.	Exp Mol Med. 2014 Oct 17;46(10):e118.
Rabbit right atrium	0.1-10 µM	30 minutes	Phentolamine inhibited the tachycardia induced by field stimulation in a concentration-dependent manner. This effect was prevented by benextramine treatment and antagonized 10-fold by yohimbine (1 μM) but not by prazosin (0.1 μM).	Br J Pharmacol. 1984 Mar;81(3):423-5.
Mouse pancreatic β-cells	20-100 µM		To study the inhibitory effects of phentolamine on ATP-sensitive K+ channels, results showed phentolamine significantly inhibited 86Rb efflux and ATP-sensitive K+ currents.	Br J Pharmacol. 1990 Sep;101(1):115-20.
Mouse pancreatic β-cells	10 µM		To investigate the inhibitory effect of Phentolamine on ATP-sensitive K+ channels and its impact on insulin release. Results showed that Phentolamine inhibited 86Rb efflux, indicating blockade of ATP-sensitive K+ channels, thereby increasing insulin release.	Br J Pharmacol. 1992 Sep;107(1):8-14.
Guinea-pig detrusor smooth muscle cells	3 µM - 100 µM		To investigate the effect of phentolamine on rhythmic contractions of detrusor muscle, results showed phentolamine induced concentration-dependent rhythmic contractions without affecting basal tone	Br J Pharmacol. 1984 Dec;83(4):965-71.

Rats	Wistar WI/Ico, Wistar WAG/Rij, Fischer 344	Perfusion and superfusion	1 µM	10 minutes	To evaluate the efficiency of α2-adrenoceptor-mediated inhibition of noradrenaline release, results showed an increase in noradrenaline release in all ages and strains.	Br J Pharmacol. 1994 Oct;113(2):363-8
Mice	Pancreatic β-cells	Perifusion	20-100 μM		To study the inhibitory effects of phentolamine on ATP-sensitive K+ channels, results showed phentolamine significantly inhibited 86Rb efflux and ATP-sensitive K+ currents.	Br J Pharmacol. 1990 Sep;101(1):115-20.
Guinea-pig	Detrusor smooth muscle strips	Tissue bath	3 μM -100 μM	Single administration	To investigate the effect of phentolamine on rhythmic contractions of detrusor muscle, results showed phentolamine induced concentration-dependent rhythmic contractions without affecting basal tone	Br J Pharmacol. 1984 Dec;83(4):965-71.
Rabbit	Ganglion-blocked conscious or anaesthetized rabbits	Intravenous injection	3-1000 μg/kg	Single injection	Phentolamine caused a dose-related rise in blood pressure in ganglion-blocked rabbits, which was antagonized by yohimbine (1 mg kg-1). In rabbits without ganglion blockade, phentolamine did not evoke a pressor response.	Br J Pharmacol. 1984 Mar;81(3):423-5.
Sprague-Dawley rats	Hippocampal slices	Perfusion	50 μM	30 minutes	To study the long-term effects of NE and phentolamine on synaptic responses in the hippocampal dentate gyrus. Results showed that NE and phentolamine selectively potentiated responses to medial PP stimulation while depressing responses to lateral PP stimulation.	Proc Natl Acad Sci U S A. 1989 Jun;86(12):4776-80

NCT03240822	Urologic Injuries ... More >> Genital Diseases, Male Amputation Less <<	Phase 1	Recruiting	December 2025	United States, North Carolina ... More >> Wake Forest School of Medicine Recruiting Winston-Salem, North Carolina, United States, 27104 Contact: Mary-Clare Day, RN BSN 336-713-1343 Mday@wakehealth.edu Less <<
NCT01422616	Ischemic Stroke ... More >> High Blood Pressure Less <<	Phase 3	Recruiting	February 2019	Australia, New South Wales ... More >> Royal Prince Alfred Hospital Recruiting Sydney, New South Wales, Australia, 2050 Contact: Craig S Anderson, MD +61 2 933 4500 canderson@georgeinstitute.org.au Less <<
NCT00226096	CVA (Cerebrovascular Accident)... More >> Cerebral Hemorrhage Intracranial Hemorrhages Less <<	Not Applicable	Completed	-	Australia, New South Wales ... More >> Concord Hospital Concord, New South Wales, Australia, 2138 Gosford Hospital Gosford, New South Wales, Australia, 2250 St George Hospital Kogarah, New South Wales, Australia, 2217 John Hunter Hospital Newcastle, New South Wales, Australia, 2310 St Vincent's Hospital Sydney, New South Wales, Australia, 2010 Royal Prince Alfred Hospital Sydney, New South Wales, Australia, 2050 Westmead Hospital Westmead, New South Wales, Australia, 2145 Australia, South Australia Royal Adelaide Hospital Adelaide, South Australia, Australia, 5000 Australia, Victoria Royal Melbourne Hospital Melbourne, Victoria, Australia, 3050 St Vincent's Hospital Melbourne, Victoria, Australia, 3065 Box Hill Hospital Melbourne, Victoria, Australia, 3128 Alfred Hospital Melbourne, Victoria, Australia, 3181 Austin Health Melbourne, Victoria, Australia Monash Medical Centre Melbourne, Victoria, Australia Australia, Western Australia Sir Charles Gairdner Hospital Perth, Western Australia, Australia, 6009 China Regional Coordinating Centre: Peking University First Hospital Beijing, China, 100034 Hospitals in China, c/o The George Institute China Beijing, China Regional Coordinating Centre: Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Second Medical University Shanghai, China, 200025 New Zealand North Shore Hospital Auckland, New Zealand Christchurch Hospital Christchurch, New Zealand Less <<
NCT01032694	-		Terminated(This study was term... More >>inated January 11, 2011 due to low enrollment. This study is not being terminated because of safety or efficacy concerns.) Less <<	-	-
NCT01032694	-		Terminated(This study was term... More >>inated January 11, 2011 due to low enrollment. This study is not being terminated because of safety or efficacy concerns.) Less <<	-	-
NCT03752957	-		Not yet recruiting	October 2019	-
NCT00577876	Prostate Cancer	Not Applicable	Completed	-	United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00104104	Multiple Myeloma	Phase 4	Completed	-	-
NCT02966665	Chronic Obstructive Pulmonary ... More >>Disease Pulmonary Artery Hypertension Heart Failure Hypertension Less <<	Phase 1	Recruiting	August 2020	United States, Utah ... More >> George E Wahlen VA Medical Center Recruiting Salt Lake City, Utah, United States, 84132 Contact: Russell Richardson, Ph.D. 801-582-1565 r.richardson@hsc.utah.edu Contact: Ashley Nelson, MD 801-582-1565 ext 4127 ash.nelson@hsc.utah.edu Less <<
NCT00716079	Intracerebral Hemorrhage ... More >> Stroke Hypertension Less <<	Not Applicable	Completed	-	-
NCT00104104	-		Completed	-	-
NCT00080808	Prostate Cancer	Phase 2	Completed	-	United States, Texas ... More >> M.D. Anderson Cancer Center at University of Texas Houston, Texas, United States, 77030-4009 Less <<
NCT00716079	-		Completed	-	-
NCT00154167	Soft Tissue Anesthesia (Numbne... More >>ss) Less <<	Phase 2	Completed	-	United States, Washington ... More >> Northwest Kinetics Tacoma, Washington, United States, 98403 Less <<
NCT00132106	Heart Failure, Congestive	Not Applicable	Unknown	-	Netherlands ... More >> Radboud University Nijmegen Medical Centre Recruiting Nijmegen, Netherlands, 6500 HB Contact: Marc ER Gomes, MD 31-24-3614533/3616550 m.gomes@cardio.umcn.nl Sub-Investigator: Marc ER Gomes, MD Sub-Investigator: Alexandra H Mulder, MD Sub-Investigator: Freek WA Verheugt, MD, PhD Sub-Investigator: Paul Smits, MD, PhD Principal Investigator: Cees J Tack, MD, PhD Sub-Investigator: Louise Bellersen, MD Less <<
NCT02584686	Vasculogenic Erectile Dysfunct... More >>ion Less <<	Phase 1	Completed	-	Egypt ... More >> Cairo University Hospitals Cairo, Egypt, 11321 Less <<
NCT02584686	-		Completed	-	-
NCT00309322	Anesthesia, Dental	Phase 2	Completed	-	United States, Massachusetts ... More >> The Forsyth Institute Boston, Massachusetts, United States, 02115 Less <<
NCT00309335	Anesthesia, Dental	Phase 3	Completed	-	United States, Massachusetts ... More >> Tufts University School of Dental Medicine Boston, Massachusetts, United States, 02111 Less <<
NCT00309361	Anesthesia, Dental	Phase 3	Completed	-	United States, Massachusetts ... More >> Tufts School of Dental Medicine Boston, Massachusetts, United States, 02111 Less <<
NCT03079921	Type1diabetes ... More >> Hypoglycemia Hypoglycemia Unawareness Less <<	Early Phase 1	Recruiting	December 2020	United States, Pennsylvania ... More >> University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Eileen Markmann 215-350-0364 eileen.markmann@uphs.upenn.edu Contact: Cornelia Dalton Bakes 2155274490 ext Dalton Bakes cornelia.dalton-bakes@uphs.upenn.edu Principal Investigator: Michael R Rickels, MD., MS Less <<
NCT03098680	Drug-Related Side Effects and ... More >>Adverse Reactions Cardiovascular System Disease Less <<	Phase 1	Recruiting	February 29, 2020	United Kingdom ... More >> Addenbrooke's Hospital Recruiting Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ Contact: Joseph Cheriyan, MBChB, MA, FRCP jc403@medschl.cam.ac.uk Less <<
NCT03318094	Insulin Resistance ... More >> Healthy Obesity Less <<	Phase 1	Recruiting	November 30, 2025	United States, Tennessee ... More >> Autonomic Dysfunction Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Misty D Hale, CCRP 615-343-8649 autonomics@vanderbilt.edu Contact: Jorge E Celedonio 6153223304 autonomics@vanderbilt.edu Less <<
NCT03033537	-		Completed	-	-
NCT02995291	Anesthesia, Local	Phase 4	Recruiting	February 2019	Canada, Nova Scotia ... More >> Dalhousie University Faculty of Dentistry Recruiting Halifax, Nova Scotia, Canada, B3H 4R2 Contact: Pierre-Luc Michaud, MSc 902-494-4264 PL.Michaud@Dal.ca Principal Investigator: Pierre-Luc Michaud, MSc Less <<
NCT02861378	Soft Tissue Anaesthesia	Not Applicable	Completed	-	Canada, Nova Scotia ... More >> Dalhousie University Faculty of Dentistry Halifax, Nova Scotia, Canada, B3H 4R2 Less <<
NCT01703559	Night Vision Complaints	Phase 2	Completed	-	United States, Arizona ... More >> Celerion Phoenix, Arizona, United States, 67230 Less <<
NCT01474382	Dental Anesthesia ... More >> Anesthesia, Local Anesthesia, Reversal Less <<	Phase 4	Completed	-	United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94143 United States, Indiana Indiana University School of Dentistry Indianapolis, Indiana, United States, 46202 United States, Ohio Nationwide Children's Hospital Columbus, Ohio, United States, 43205 United States, Pennsylvania University of Pennsylvania School of Dental Philadelphia, Pennsylvania, United States, 19104-6030 University of Pittsburgh School of Dental Medicine Pittsburgh, Pennsylvania, United States, 15261 United States, Utah Jean Brown Research Salt Lake City, Utah, United States, 84124 United States, Washington Center for Pediatric Dentistry Seattle`, Washington, United States, 98115 Less <<
NCT03740386	Anesthesia, Local	Not Applicable	Completed	-	-

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.65mL 0.53mL 0.26mL	13.25mL 2.65mL 1.32mL	26.49mL 5.30mL 2.65mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2 The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 65-28-1

{[proInfo.proName]}

CAS No.: 65-28-1

Alternative Products

Product Details of Phentolamine methanesulfonate salt

Safety of Phentolamine methanesulfonate salt

Related Pathways of Phentolamine methanesulfonate salt

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator